Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups

With the recent FDA approval of tumor mutational burden-high (TMB-H) status as a biomarker for treatment with a PD-1 inhibitor regardless of tumor type, accurate assessment of patient-specific TMB is more critical now more than ever. Using paired tumor and germline exome sequencing data from 701 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Asmann, Yan W., Parikh, Kaushal, Bergsagel, P. Leif, Dong, Haidong, Adjei, Alex A., Borad, Mitesh J., Mansfield, Aaron S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979755/
https://www.ncbi.nlm.nih.gov/pubmed/33742076
http://dx.doi.org/10.1038/s41698-021-00164-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979755/
https://www.ncbi.nlm.nih.gov/pubmed/33742076
http://dx.doi.org/10.1038/s41698-021-00164-5

Ejemplares similares